These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 7950860)
1. Exploration of mucosal immunity in humans: relevance to vaccine development. Czerkinsky C; Holmgren J Cell Mol Biol (Noisy-le-grand); 1994; 40 Suppl 1():37-44. PubMed ID: 7950860 [TBL] [Abstract][Full Text] [Related]
2. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723 [TBL] [Abstract][Full Text] [Related]
3. New perspectives in vaccine development: mucosal immunity to infections. McGhee JR; Kiyono H Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356 [TBL] [Abstract][Full Text] [Related]
4. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Mestecky J; Michalek SM; Moldoveanu Z; Russell MW Behring Inst Mitt; 1997 Feb; (98):33-43. PubMed ID: 9382757 [TBL] [Abstract][Full Text] [Related]
6. Human circulating specific antibody-forming cells after systemic and mucosal immunizations: differential homing commitments and cell surface differentiation markers. Quiding-Järbrink M; Lakew M; Nordström I; Banchereau J; Butcher E; Holmgren J; Czerkinsky C Eur J Immunol; 1995 Feb; 25(2):322-7. PubMed ID: 7533081 [TBL] [Abstract][Full Text] [Related]
7. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. Quiding-Järbrink M; Nordström I; Granström G; Kilander A; Jertborn M; Butcher EC; Lazarovits AI; Holmgren J; Czerkinsky C J Clin Invest; 1997 Mar; 99(6):1281-6. PubMed ID: 9077537 [TBL] [Abstract][Full Text] [Related]
8. New generation of mucosal adjuvants for the induction of protective immunity. Yuki Y; Kiyono H Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340 [TBL] [Abstract][Full Text] [Related]
9. Mucosal responses to parenteral and mucosal vaccines. Kaul D; Ogra PL Dev Biol Stand; 1998; 95():141-6. PubMed ID: 9855424 [TBL] [Abstract][Full Text] [Related]
10. Induction of specific immunity at mucosal surfaces: prospects for vaccine development. Czerkinsky C; Quiding M; Eriksson K; Nordström I; Lakew M; Wenerås C; Kilander A; Björck S; Svennerholm AM; Butcher E Adv Exp Med Biol; 1995; 371B():1409-16. PubMed ID: 7502829 [TBL] [Abstract][Full Text] [Related]
11. Mucosal immunity: regulation by helper T cells and a novel method for detection. Jackson RJ; Marinaro M; VanCott JL; Yamamoto M; Okahashi N; Fujihashi K; Kiyono H; Chatfield SN; McGhee JR J Biotechnol; 1996 Jan; 44(1-3):209-16. PubMed ID: 8717406 [TBL] [Abstract][Full Text] [Related]
12. New perspectives in mucosal immunity with emphasis on vaccine development. McGhee JR; Fujihashi K; Xu-Amano J; Jackson RJ; Elson CO; Beagley KW; Kiyono H Semin Hematol; 1993 Oct; 30(4 Suppl 4):3-12; discussion 13-5. PubMed ID: 8303308 [TBL] [Abstract][Full Text] [Related]
13. Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus. Mestecky J; Kutteh WH; Jackson S AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S11-20. PubMed ID: 7865284 [TBL] [Abstract][Full Text] [Related]
14. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. Imaoka K; Miller CJ; Kubota M; McChesney MB; Lohman B; Yamamoto M; Fujihashi K; Someya K; Honda M; McGhee JR; Kiyono H J Immunol; 1998 Dec; 161(11):5952-8. PubMed ID: 9834076 [TBL] [Abstract][Full Text] [Related]
15. Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. Kubota M; Miller CJ; Imaoka K; Kawabata S; Fujihashi K; McGhee JR; Kiyono H J Immunol; 1997 Jun; 158(11):5321-9. PubMed ID: 9164952 [TBL] [Abstract][Full Text] [Related]
16. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice. Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512 [TBL] [Abstract][Full Text] [Related]
17. The immunologic aspects of human immunodeficiency virus infection in the gastrointestinal tract. Schneider T; Ullrich R; Zeitz M Semin Gastrointest Dis; 1996 Jan; 7(1):19-29. PubMed ID: 8903576 [TBL] [Abstract][Full Text] [Related]
18. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. Yanagita M; Hiroi T; Kitagaki N; Hamada S; Ito HO; Shimauchi H; Murakami S; Okada H; Kiyono H J Immunol; 1999 Mar; 162(6):3559-65. PubMed ID: 10092814 [TBL] [Abstract][Full Text] [Related]
19. In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. McGhee JR; Mestecky J Infect Dis Clin North Am; 1990 Jun; 4(2):315-41. PubMed ID: 2189002 [TBL] [Abstract][Full Text] [Related]
20. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice. Sasaki K; Kato M; Takahashi T; Ochi S; Ichinose Y; Shiraki K; Asano Y; Iwanaga M; Tsuji T J Med Virol; 2003 Jun; 70(2):329-35. PubMed ID: 12696126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]